Can medical cannabis help children—and what does the evidence actually show? Pediatric pharmacologist, Dr. Lauren Kelly, joins Trevor and Kirk to discuss medical cannabis in children. This wide ranging conversation includes discussion about epilepsy, autism, pediatric oncology, and the unique challenges of studying cannabinoids during development. Learn what researchers know about CBD, THC & kids, why evidence remains relatively limited, and how stigma, policy, and education continue to affect patient care. Listen now for an evidence-based discussion on pediatric cannabis research, safety, and the future of cannabinoid medicine for children.

Can medical cannabis care become more personalized and patient-focused? Trevor and Kirk talk with Seann Poli of JANrx about raising capital during the early LP boom to building a 100% Canadian, independent medical cannabis company. Seann tells us about veteran cannabis care, challenges dealing with insurance companies, CBD/CBN products, medical cannabis education, and the future of holistic cannabinoid wellness in Canada. Learn how personalized cannabis support is helping veterans manage PTSD, sleep, pain, and overall health for veterans and civilians alike.

Can a massive data project finally answer the biggest questions about medical cannabis? In Part 2 of our conversation with Dr. Johannes Thrul, we explore the National Cannabis Study, an ambitious effort to build a global repository of cannabis research and real-world patient data. From standardized tools like the Cannabis Use Questionnaire to combining datasets from multiple studies, this project aims to uncover how cannabis truly impacts conditions like chronic pain, anxiety, PTSD, and insomnia. With AI analysis, collaborative research, and a goal of 10,000 participants, the team hopes to transform fragmented cannabis studies into one powerful evidence base. Listen now to learn how this groundbreaking cannabis database could reshape the future of cannabis medicine.

What will it take for cannabis and natural compounds to truly enter the mainstream—from toothpaste to energy drinks? In Part 2 of Trevor and Kirk’s conversation with biotech financier and cannabis strategist David Traylor, they discuss how major corporations might explore integrating cannabinoids like CBN and CBD and other natural products into everyday consumer products. David explains how his Skunk Works Nature AI advisory group connects global companies with world-class experts in pharmacology, biotechnology, and regulatory strategy to develop cannabinoid and other natural product based innovations. From potential sleep-supporting CBN toothpaste, to the role of pharmacogenomics and personalized medicine, this episode explores how science, investment, and product development intersect in the cannabis, psychedelic and natural product sectors. Trevor and Kirk also unpack the broader forces shaping the cannabis industry—stigma, regulatory barriers, banking challenges, and the tension between single-molecule pharmaceutical approaches vs. whole-plant medicine. Could big brands like PepsiCo or Red Bull be the catalyst that finally normalizes cannabinoid ingredients in consumer products? And what role does fear, policy, and economics play in slowing cannabis acceptance? Listen now to learn how cannabis science, biotech innovation, and big-industry investment could reshape the future of medicine, consumer products, and natural compounds.